Prostate Cancer

Three-Month Formulation Of Drug Approved By FDA

Published in Drug Week, August 17th, 2001

The Swiss-based pharmaceutical company Debiopharm S.A., part of the Debio group, announced that the U.S. Food and Drug Administration (FDA) has granted marketing authorization for Debiopharm's luteinizing hormone releasing hormone (LHRH) agonist, triptorelin pamoate, Trelstar^TM LA, to treat advanced-stage prostate cancer.

Trelstar LA is a controlled-release formulation of triptorelin which delivers triptorelin continuously over a period of three months after intramuscular injection. Extensive clinical studies comparing the effectiveness of the already approved one-month controlled-release formulation of triptorelin (Trelstar Depot 3.75 mg) and the new...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2001-08-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry